youtube_live
Q2 2026 财报 • 已发布 • 收入超出预期 +47.38%
查看结果chevron_right
ABVX:EPA
Abivax SA
€86.40
arrow_downward
-4.69%(-4.25) 1 天
9月22日, GMT+2 17:35:09 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ABVX 生成关键数据洞见…
开盘价
€88.95
最高价
€90.95
最低价
€84.60
市值
77.17亿
平均成交量
13.98万
成交量
16.96万
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€4.49
流通股数
8735.00万
员工人数
80
开盘价
€88.95
最高价
€90.95
最低价
€84.60
市值
77.17亿
平均成交量
13.98万
成交量
16.96万
52 周最高价
€139.00
52 周最低价
€60.45
每股收益
-€4.49
流通股数
8735.00万
员工人数
80
新闻报道
来自网络来源和新闻合作伙伴
Idéal Investisseur
·
9小时前
Abivax shares among the steepest declines on the SBF 120, under pressure despite its results
资料
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA简介